Bank of New York Mellon Corp lowered its holdings in shares of Exelixis, Inc. (NASDAQ: EXEL) by 2.8%

Exelixis (EXEL) possesses the right combination of the two key ingredients for a likely earnings bea

Allspring Global Investments Holdings LLC grew its holdings in Exelixis, Inc. (NASDAQ: EXEL) by 23.4

Exelixis (EXEL) has an impressive earnings surprise history and currently possesses the right combin

Barclays analyst Etzer Darout maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raises the

Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and r

These three biotechs are posting strong revenue growth. Brand-new launches and label expansions shou

Exelixis' zanzalintinib faces a setback, but an FDA review, phase III trials and Cabometyx momentum

Biotechnology stocks like Illumina, Eli Lilly and Exelixis have quietly turned into the new market l

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

Investors interested in Medical - Biomedical and Genetics stocks are likely familiar with Exelixis (

Exelixis (EXEL) is at a 52-week high, but can investors hope for more gains in the future? We take a

RBC Capital analyst Leonid Timashev maintains Exelixis (NASDAQ:EXEL) with a Sector Perform and ra

Truist Securities analyst Gregory Renza maintains Exelixis (NASDAQ:EXEL) with a Hold and raises t

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the

UBS analyst Ashwani Verma maintains Exelixis (NASDAQ:EXEL) with a Neutral and raises the price ta

HC Wainwright & Co. analyst Robert Burns reiterates Exelixis (NASDAQ:EXEL) with a Buy and mai

Wall Street analysts change outlook on top names, with downgrades and initiations. See analyst ratin

Truist Securities analyst Gregory Renza downgrades Exelixis (NASDAQ:EXEL) from Buy to Hold and ra

Citizens analyst Silvan Turkcan maintains Exelixis (NASDAQ:EXEL) with a Market Outperform and rai

Exelixis falls after STELLAR-303 misses statistical significance in overall survival for a key color

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Exelixis reported final STELLAR-303 data showing a survival trend for zanzalintinib combo in metasta

Exelixis, Inc. (NASDAQ:EXEL) today announced results from the final analysis of the dual primary end

ALAMEDA, Calif.--(BUSINESS WIRE)--Exelixis, Inc. (Nasdaq: EXEL) today announced results from the fin

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

Wondering how to pick strong, market-beating stocks for your investment portfolio? Look no further t

Drug adoption and a strong pipeline see institutions send Exelixis, Inc. (EXEL) shares to all-time h

Exelixis, Inc. (EXEL) Presents at Goldman Sachs 47th Annual Global Healthcare Conference 2026 Transc

Exelixis (EXEL) reported earnings 30 days ago. What's next for the stock?

The Zacks Style Scores offers investors a way to easily find top-rated stocks based on their investi

STELLAR-316 is a planned phase 3 pivotal trial in patients with resected stage II/III colorectal can

Top Wall Street analysts changed their outlook on top names. See all rating changes, including upgra

HC Wainwright & Co. analyst Robert Burns maintains Exelixis (NASDAQ:EXEL) with a Buy and rais

TD Cowen analyst Yaron Werber maintains Exelixis (NASDAQ:EXEL) with a Buy and raises the price ta

Morgan Stanley analyst Sean Laaman maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and raise

Stifel analyst Stephen Willey maintains Exelixis (NASDAQ:EXEL) with a Hold and raises the price t

Wells Fargo analyst Eva Fortea Verdejo maintains Exelixis (NASDAQ:EXEL) with a Equal-Weight and r

Dr. Morrissey continued: "Our R&D organization is on track to deliver multiple milestones th

Exelixis (NASDAQ:EXEL) affirms FY2026 sales outlook from $2.525 billion-$2.625 billion to $2.525 bil

Exelixis (NASDAQ:EXEL) reported quarterly earnings of $0.87 per share which beat the analyst consens

Merck stock falls as the Phase 3 LITESPARK-012 trial for advanced renal cell carcinoma fails to meet

Companies Reporting Before The Bell • Kosmos Energy (NYSE:KOS) is expected to report quarterly earn